Bill Sellers, head of Broad’s Cancer Program, talks about how to discover new classes of genetic dependencies that could move therapies closer to curing cancer patients.
Large-scale collaboration will leverage each institution’s expertise and infrastructure to advance understanding of the biological basis of pediatric cancers, identify new vulnerabilities of these diseases and accelerate cures globally
Scientists have solved the structure of an important complex of RAS-pathway proteins, explaining how known mutations lead to disease and suggesting potential new binding sites for cancer drugs.
Joint initiative will develop comprehensive collection of molecularly and functionally characterized rare cancer tumor models to inform novel therapeutic strategies